

Referenzen

1. Andre T, Lonardi S, Lenz H-J, et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Subgroup efficacy and expanded safety analyses from CheckMate 8HW. ESMO Congress 2024, Abstract number 541P.
2. Sara L, Thierry A, Dirk A, et al. Health-related quality of life with first-line nivolumab plus ipilimumab vs chemotherapy in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: CheckMate 8HW. ESMO Gastrointestinal Cancers Annual Congress 2024; Abstract number 312.